gptkbp:instance_of
|
gptkb:biotechnology
|
gptkbp:acquisition
|
gptkb:Loxo_Oncology
|
gptkbp:awards
|
gptkb:Innovative_Medicines_Initiative
Best Places to Work
Most Innovative Companies
Top 10 Biotech Companies
Fastest Growing Companies
|
gptkbp:can_lead_to
|
gptkb:BLU-285
gptkb:BLU-554
gptkb:BLU-667
gptkb:BLU-701
|
gptkbp:ceo
|
Kate Haviland
|
gptkbp:clinical_trial
|
ongoing
Phase 1
Phase 2
Phase 3
|
gptkbp:collaboration
|
gptkb:Foundation_Medicine
|
gptkbp:collaborations
|
academic institutions
|
gptkbp:employees
|
over 200
|
gptkbp:focus
|
targeted therapies
|
gptkbp:founded
|
gptkb:2011
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
gptkbp:healthcare
|
gptkb:Avapritinib
gptkb:Pralsetinib
|
https://www.w3.org/2000/01/rdf-schema#label
|
Blueprint Medicines
|
gptkbp:instruction_set
|
therapeutics
|
gptkbp:investment
|
Venture capital firms
|
gptkbp:partnership
|
gptkb:Merck
gptkb:Zymeworks
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Vertex_Pharmaceuticals
gptkb:Cure_Vac
gptkb:Novartis
gptkb:Takeda
|
gptkbp:research_and_development
|
highly selective inhibitors
|
gptkbp:research_areas
|
rare diseases
|
gptkbp:research_focus
|
genetic drivers of cancer
|
gptkbp:specializes_in
|
gptkb:cancer_treatment
|
gptkbp:stock_symbol
|
BPMC
|
gptkbp:target_market
|
oncology
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
gptkbp:website
|
blueprintmedicines.com
|
gptkbp:bfsParent
|
gptkb:biotechnology
|
gptkbp:bfsLayer
|
3
|